Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Hematologic Neoplasms 2

Interventions

Olanzapine 4Cyclophosphamide 4Voriconazole 3Tranexamic Acid 3Standard of Care 3nilotinib 2letermovir 2fludarabine phosphate 2Zoledronic Acid 2Whole-Body Irradiation 2Practice Guidelines as Topic 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Methods 2Imatinib Mesylate 2Educational Status 2Early Intervention, Educational 2Doxorubicin 2Cyclosporins 2Cyclosporine 2venetoclax 1trihexyltetradecylphosphonium chloride 1thymoglobulin 1shengxuening 1posaconazole 1pembrolizumab 1olaparib 1maribavir 1lenvatinib 1ferrous succinate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Hematologic Neoplasms × letermovir × Clear all
NCT05711667 2026-05-05

A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients

Children's Oncology Group

Phase 3 Recruiting
105 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

NCT06449586 2025-12-15

CMV-specific T Cell Immunity Test Indicated Prophylaxis of Letermovir After All-HSCT

Ruijin Hospital

Phase 3 Active not recruiting
250 enrolled
Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡